Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Study type: Observational

Funder types: Industry

Identifiers

NCT00659607

502.475

Details and patient eligibility

About

This Post Marketing Surveillance (PMS) study aims to review the followings by investigating the actual practice of MicardisPlus Tablet on the market:

1. Unexpected adverse drug reactions (especially, serious adverse events (SAEs))
2. Frequency of incidence and its change in adverse events (AEs)
3. Factors on the safety profile of the study drug
4. Factors on the efficacy profile of the study drug

Enrollment: 6,901 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

patients diagnosed with essential hypertension

Exclusion criteria

patients who took Micardis Plus before participating in this PMS study